ライフサイエンスコーパス: medication

1 who received at least one injection of study medication.

2 s varied significantly with type of sedation medication.

3 lmic disease, overall and for each available medication.

4 olled, 81.5% (81.3-81.6) were using only one medication.

5 incipal investigators to be related to study medication.

6 re scanned while on their usual dopaminergic medication.

7 ates that OSU6162 might serve as a novel BED medication.

8 , which was considered as unrelated to study medication.

9 d psychiatric history or recent psychoactive medication.

10 than 4 weeks who consented to treatment with medication.

11 ular disease, and no use of antihypertensive medication.

12 ndary outcome reductions in glucose-lowering medication.

13 primary risk factor was receipt of sedation medication.

14 among users of these 2 disparate classes of medication.

15 rtly accounted for by cognitive deficits and medication.

16 umber of platelets and regular need for pain medication.

17 he World Health Organization as an essential medication.

18 s who have not been exposed to antipsychotic medication.

19 and training in administration of emergency medication.

20 mitant ITP medication discontinued 1 or more medication.

21 compliance with absence of antihypertensive medication.

22 aring performance ON and OFF prodopaminergic medication.

23 educing the clinical symptoms and the use of medication.

24 usly recognised; and contaminated compounded medications.

25 nhaled corticosteroids plus other controller medications.

26 s consistently taking prescribed life-saving medications.

27 significant reduction in requirements of DM medications.

28 maintained on stable doses of antipsychotic medications.

29 sex, adiposity, and the use of psychoactive medications.

30 nd on improving treatment retention for both medications.

31 l side effect of many marketed and withdrawn medications.

32 judgement of the cost/benefit trade-off for medications.

33 ) due to fewer hypoglycemic events and fewer medications.

34 h within and across different antidepressant medications.

35 n [34.6%]), 47.3% were taking antithrombotic medications.

36 k profile, and benefits, harms, and costs of medications.

37 responsive to conventional pressure-reducing medications.

38 r baseline characteristics and postprocedure medications.

39 oor adherence to prescribed antihypertensive medications.

40 Nurses and carers administering medications.

41 r opioids, and also possibly for psychiatric medications.

42 ers for assessment of the bone safety of new medications.

43 lled with over-the-counter anti-inflammatory medications.

44 the impact of psychiatric co-morbidities and medications.

45 and reduction in the number of antiglaucoma medications.

46 k of bias (including 3 that studied dementia medications, 16 antihypertensives, 4 diabetes medication

47 edications, 16 antihypertensives, 4 diabetes medications, 2 nonsteroidal anti-inflammatory drugs [NSA

48 s with chronic schizophrenia who were taking medication, 23 healthy first-degree relatives of patient

49 Among U.S. adults taking antihypertensive medication, 53.4% (95% CI: 49.9% to 56.8%) and 39.0% (95

50 Of the 991 patients using lethal self-medication, 762 (77%) recipients had cancer, 79 (8%) had

51 hysician preference largely determined which medication a patient received (OR = 3.13; p = 3 x 10(-37

52 mpared with patients who continued the study medications) a lower risk of major cardiovascular events

53 tive, medical history, critical appraisal of medications, a meeting between the treating elder care p

54 P </= 12 mm Hg without and with antiglaucoma medications (absolute success and qualified success, res

55 Brand medications accounted for a significantly higher proport

56 to eye care providers is driven by glaucoma medications, accounting for $1.2 billion (54% of total c

57 impact of patient-provider communication on medication adherence among a sample of primary care prov

58 ted through an adverse effect of cannabis on medication adherence is unclear.

59 This measure was also used to assess medication adherence on the basis of both face-to-face i

60 matched control and medical home practices, medication adherence was significantly higher in medical

61 n between patient-provider communication and medication adherence, there are no empirical data on how

62 iated through the effects of cannabis use on medication adherence.

63 ing and multi-compartment compliance aids on medication administration accuracy.

64 significant difference in, and high overall, medication administration error rate between original me

65 The medication administration error rate was calculated as t

66 m 2493 opportunities for error (7.1% overall medication administration error rate).

67 Similar differences existed when comparing medication administration error rates between original m

68 nvestigation of tablet and capsule impact on medication administration errors and staff training to p

69 One hundred and seventy eight medication administration errors were identified from 24

70 inistered (or omitted) in error according to medication administration records, compared to the oppor

71 ister medications to 823 residents during 90 medication administration rounds.

72 n care homes that used a combination of both medication administration systems (RR=4.3, 95%CI 2.7 to

73 which they had blood draws before and after medication administration.

74 chances of nonadherence to immunosuppressive medication after HTx, but the elevation of mortality haz

75 r the immunomodulatory and immunosuppressive medication against hepatitis C was the key reason for th

76 Additional trials of medications aimed at targeting cytokine overactivity tha

77 ents who received at least one dose of trial medication (analysed according to the actual treatment r

78 avoidance advice, patient specific emergency medication and an emergency treatment plan and training

79 et and exercise, physical and mental health, medication and BMI outcome measures.

80 patients were randomized between oral study medication and CBT (2:1) for 24 weeks.

81 rmacotherapy should be started and choice of medication and duration of treatment will maximize the b

82 treatment failure to CBT and antidepressant medication and survived application of the subsample per

83 ity scores were associated with remission to medication and treatment failure with CBT.

84 Secondly, use of medication and treatment satisfaction in AR and NAR was

85 lternatives, currently approved anti-obesity medications and best practices to individualize the sele

86 also gathered information on treatment with medications and confounding factors, such as substance u

87 fective in those with fewer antihypertensive medications and higher baseline sBP up to 170 mmHg.

88 ionable information to help further optimize medications and improve outcomes.

89 -2015) to examine prescriptions for diabetes medications and supplies as a measure of postdonation di

90 e Part D prescribing patterns for ophthalmic medications and to estimate the potential savings of gen

91 ted sufficiently with primarily IOP lowering medications and without need for glaucoma surgery.

92 reinforcing effects of chronic dopaminergic medication, and a potential role for individual suscepti

93 stigated thus far have been on antipsychotic medication, and as these compounds may dampen immune cel

94 er of days of use of acute migraine-specific medication, and change in scores on the physical-impairm

95 er C-reactive protein, regular need for pain medication, and higher lactate dehydrogenase had a negat

96 category, moderate if there was a change in medication, and low if there was no change.

97 ions of recommendations for antihypertensive medication, and prevalence of BP above the treatment goa

98 n average of one additional antihypertensive medication, and the systolic blood pressure was 14.8 mm

99 f lymphoma compared with exposure to neither medication, and this risk was higher with combination th

100 has been stable and inactive on appropriate medications, and assess relevant risk factors including

101 eristics, clinical variables, comorbidities, medications, and biomarkers into Cox proportional hazard

102 ial), compare effectiveness of antiepileptic medications, and rigorous examination of effectiveness o

103 However, these medications are associated with severe side effects, and

104 New medications are being explored, such as pioglitazone, wh

105 Depression and use of antidepressant medications are both associated with increased risk of o

106 High-value medications are not preferentially used.

107 (5-HT2A) receptors, or both; however, these medications are not universally effective, they may prod

108 When available, medications are unaffordable for most patients.

109 Tobacco cessation medications are unavailable in the Kerala public sector

110 s, and other central nervous system-targeted medications) are increasingly used for treatment of func

111 heir blood pressure daily and 43% took their medications as prescribed.

112 rehydration solutions, antibiotics and other medications as well as education provided to the primary

113 Greater integration of medication-assisted treatment (MAT) for opioid use disor

114 hort of new patients prescribed dermatologic medications at a single, urban, safety-net hospital outp

115 s reported morbidity in patients using these medications at admission to ICU.

116 Use of asthma rescue medications at cohort entry reduced the risk of developi

117 edicare negotiated the prices for ophthalmic medications at USVA rates, $1.09 billion would be saved

118 15-min resting-state EEGs were recorded off medication (baseline).

119 Of the 120 patients taking antiarrhythmic medications before CSD, 39 (32%) no longer required them

120 Medication beliefs and habit strength are modifiable tar

121 al equation modeling, we modeled illness and medication beliefs as mediators of the relationship betw

122 and the time until patients required rescue medication, both showing statistical significance of the

123 Adverse events were common with medications but not with CBT and were not severe.

124 affects the brain and behavior, (2) whether medications can be developed to treat cannabis use disor

125 Although the currently approved medications can reliably reduce the viral load and preve

126 an and the pharmacist, and implementation of medication changes.

127 nerated the highest percentage of brand name medication claims compared with all other providers.

128 An interaction between medication classes for additive, synergistic, or antagon

129 Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in pre

130 ts in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications,

131 Medication conditions were separated by a washout period

132 We also examined the association of medication cost with availability and prescription patte

133 05 307 vs. $118 854), primarily due to lower medication costs ($34 521 vs. $48 763).

134 rtality rates, costs (inpatient, outpatient, medication costs) and utilization (visits, hospitalizati

135 Current directions in medication development for alcohol use disorder (AUD) em

136 %) of 101 patients receiving concomitant ITP medication discontinued 1 or more medication.

137 ies for African Americans (eg, heart failure medications), disease management is less effective among

138 urrent asthma at age 7 was defined by asthma medications dispensed at least twice in the year (1,901

139 mpared with conventional medications, herbal medications do not require clinical studies before their

140 Finally, we show that anti-psychotic medications dose-dependently increase claudin-5 expressi

141 ations in the gut microbiome and intensified medication due to a flare of the disease.

142 could have been avoided if they had received medication during the entire follow-up.

143 DAT1 genotype significantly moderated medication effects, such that APZ, relative to placebo,

144 are associated with either disease state or medication effects.

145 Eye symptoms than those treated with topical medications (eg, at 12 months, 153 of 269 [56.9%] vs 11

146 ervation, and self-reports, pill counts, and medication event-monitoring devices for self-administrat

147 ebo-controlled trial (RCT) of antidepressant medication for 10-week's duration in patients with dysth

148 Patients initiating therapy with common medications for chronic diseases (diabetes, hypertension

149 a to prevent attacks, and discontinuation of medications for chronic gout in adults.

150 Several systemic medications for low back pain are associated with small

151 Clozapine is one of the most promising medications for managing schizophrenia but it is under-u

152 ing use of antipsychotics and other sedating medications for treatment of severe agitation that poses

153 l outcomes included organ-specific symptoms, medication-free days, rhinitis severity and asthma contr

154 tal cortex (Brodmann Area 9) of sudden death medication-free individuals post mortem.

155 METHOD: A total of 154 medication-free patients with major depressive disorder

156 who reported currently taking lipid-lowering medication, full implementation of the USPSTF recommenda

157 Having 1 or more AEs related to medication, gastrointestinal AE, laboratory abnormality,

158 Stimulant medication has long been effective in treating attention

159 adix puerariae, a traditional Chinese herbal medication, has been used to treat patients with diabeti

160 Compared with conventional medications, herbal medications do not require clinical

161 and clinical outcomes associated with these medications, highlighting recent large cardiovascular ou

162 Patient demographics, medical and medication history, and clinical characteristics of pati

163 No class of medications (i.e., angiotensin-converting enzyme inhibit

164 Which medication, if any, to use to prevent the headache of pe

165 T2 PET changed the diagnosis in 11 (23%) and medication in 25 (53%) participants.

166 s Data and Information Set (HEDIS) high-risk medication in older adults (PUM-HEDIS), any daily exposu

167 y subjects with "active asthma" (symptoms or medication in the last year, n = 744) were analyzed in t

168 d severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis

169 Here we document self-medication in the only Asian great ape, orang-utans (Pon

170 f chronic pulmonary disease or use of asthma medication in the past 5 years.

171 increased nonadherence to immunosuppressive medication in this age window.

172 directly observed solid, orally administered medications in tablet or capsule form at ten purposively

173 ning what factors predict when withdrawal of medications in those who are seizure free is propitious.

174 ed rate of manic episodes within 3 months of medication initiation (hazard ratio=6.7, 95% CI=2.0-22.4

175 Nonadherence to antidepressant medication is common and leads to poor outcomes.

176 Indeed, curing HCV infection with an oral medication is now reality.

177 ligand agents) is recommended when a single medication is unsuccessful or produces side effects at h

178 Complete remission off anti-seizure medications is possible, but future efforts should be di

179 mation on patients' disease activity scores, medications, laboratory assessments, and clinical examin

180 INTERPRETATION: Advances in medications, lifestyle, and socioeconomics might compres

181 e) was retrospectively queried from the home medication list of the preoperative evaluation.

182 rugs and xenobiotics, long-term use of these medications may affect fetal drug exposure by altering B

183 ere D2 receptors are abundant, antipsychotic medications may affect neural function in studies of ani

184 These findings suggest that ADHD medications may help ameliorate educationally relevant o

185 ctures are unclear (very low SOE), and these medications may increase risk for some safety outcomes.

186 was subdivided by (1) treatment status: off medication (n=4) or on medication (n=9); or (2) treatmen

187 treatment status: off medication (n=4) or on medication (n=9); or (2) treatment response: treatment r

188 Medication nonadherence, a major problem in cardiovascul

189 No difference in associations between medications of interest and second breast cancer events

190 Current anti-diabetic medications often result in adverse weight gain and hypo

191 Effects of osteoporosis medications on BMD, fracture risk, and safety among pati

192 To understand the effects of psoriasis medications on systemic inflammation associated with car

193 with a cumulative benefit of evidence-based medications on this cause of death.

194 n, patients indicated whether they preferred medication or CBT or had no preference.

195 (n = 3), azithromycin (n = 2), and 15 other medications or dietary supplements.

196 ng, prior antibiotic use, adherence to study medication, or development of urinary tract infection du

197 bility to receive treatment with alternative medications, or relapse while receiving treatment with a

198 ted outcome measures; 3) describe prescribed medications, orders for laboratory and other tests, and

199 likely than males (13698 [24.4%]) to receive medications (P < .001), as were non-Hispanic black (105

200 administration error rates between original medication packaging (from original medication packaging

201 sampled care homes (five only used original medication packaging and five used both multi-compartmen

202 CI 1.1 to 4.9, p=0.03), and between original medication packaging and multi-compartment compliance ai

203 n administration error rate between original medication packaging and multi-compartment compliance ai

204 Compare the effect of original medication packaging and multi-compartment compliance ai

205 lti-compartment compliance aids and original medication packaging).

206 original medication packaging (from original medication packaging-only care homes) and multi-compartm

207 , but having 1 or more infections related to medication (predominantly upper airway) was less likely.

208 nalyses the probability of having had asthma medication prescribed was significantly reduced in the f

209 IGATE and community care on the psychotropic medications prescribed, side effects experienced, metabo

210 We also examined the rates of antianginal medication prescriptions at discharge.

211 lude a review of comorbidities, adherence to medications, previous episodes of near-fatal asthma, and

212 ine sociodemographic factors associated with medication receipt.

213 Treatment with an antimalarial medication reduced parasitaemia for the most prevalent h

214 ients with TDPD demonstrated improvements in medication-refractory tremor by CRST assessments, even i

215 Prevention strategies for medication-related events are reviewed by medication use

216 at 'medicinal' cannabis or cannabinoid-based medications relieve pain in human diseases such as cance

217 of contamination or substitution with other medications represents a concern.

218 up of severe childhood onset epilepsies with medication-resistant seizures and poor developmental out

219 Multidisciplinary Multistep Medication Review (3MR) consisting of an assessment of t

220 current asthma could be ruled out and asthma medications safely stopped in randomly selected adults w

221 Primary outcome was combined symptom medication score (CSMS) during grass pollen season (GPS)

222 s, with relative total combined symptom plus medication score improvement versus placebo of 21% (95%

223 primary end point was daily combined symptom-medication scores during the 2013 pollen season (area un

224 At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improve

225 e from confounding factors such as use of RA medication, selection bias and differential RA diagnosis

226 of disease where trials of anti-inflammatory medication should be focused.

227 Physicians prescribing NOAC medications should consider the potential risks associat

228 t 12 months, and who had not been taking any medication shown to improve menopausal flushes in the pr

229 diphasic dyskinesia and persisted in the off-medication state.

230 n average of 7.5 hours in 'off' dopaminergic medication state.

231 ociated with the indication and failure of a medication step-down treatment.

232 962,222 single substance exposures to the 48 medications studied.

233 ding potential (BPND) was measured in 14 off-medication subjects with SCH and 14 matched HCs at basel

234 In men, medication such as phosphodiesterase type 5 inhibitors m

235 al therapy, slow breathing and hypnosis, and medications such as venlafaxine and gabapentin.Additiona

236 Other controller medications, such as long-acting bronchodilators and bio

237 cts of communication affect patient's actual medication-taking behaviors.

238 Prognosis is poor, in part, because existing medications target only associated ASD features.

239 tients need the same doses of antidepressant medication that are used for younger adult patients.

240 This article will review medications that can lead to weight gain and potential a

241 limited to the use of saliva substitutes and medications that provide only temporary relief.

242 Among participants taking antihypertensive medication, the regression-derived thresholds for daytim

243 Medication then reduced symptoms and lessened the need f

244 with co-interventions (including systematic medication titration by doctors, pharmacists, or patient

245 urses, 6 carers) were observed to administer medications to 823 residents during 90 medication admini

246 and subsequent titration of antihypertensive medications to achieve individualised BP goals is recomm

247 haracteristics, comorbidity score, and other medications to estimate HRs and 95% confidence intervals

248 th ART after false-positive diagnosis (e.g., medication toxicities); including these outcomes would f

249 y to experience MVCs, but the effect of ADHD medication treatment on the risk of MVCs remains unclear

250 Specifically, asthma medication usage and respiratory symptoms increased [OR=

251 nd greatly on the disutility caused by daily medication use (pill burden).

252 tanding of the associations between systemic medication use and intraocular pressure (IOP) in the gen

253 Little is known about patterns of medication use and lifestyle counseling in patients with

254 To explore associations between ADHD medication use and risk of MVCs in a large cohort of pat

255 We examined associations between medication use and surveillance mammography using multiv

256 ted the association between acid-suppressing medication use and the subsequent risk of iron deficienc

257 Asthma rescue medication use appeared to reduce obesity risk independe

258 Maternal antidepressant medication use during pregnancy has previously been asso

259 e the association of maternal antidepressant medication use during pregnancy with ID in offspring and

260 rders during the 3 prior years, psychotropic medication use during the prior year, and incident fract

261 Survivor characteristics associated with medication use for depression were largely consistent wi

262 Rates of medication use in cancer survivors were compared with ra

263 is effective in discontinuing inappropriate medication use in frail nursing home residents without a

264 90 mm Hg, or self-reported antihypertensive medication use in the previous 2 weeks.

265 nicians with evidence-based guidance on safe medication use practices for the critically ill.

266 or medication-related events are reviewed by medication use process node (prescribing, distribution,

267 a stage, function, comorbidity, psychoactive medication use) and nesting effects of residents and sta

268 Nonserious harms were common with medication use, although discontinuation due to adverse

269 Secondary outcomes included pain medication use, global improvement, satisfaction with in

270 p and meta-regression analyses revealed that medication use, medical or psychiatric conditions, case-

271 Furthermore, concomitant (antiallergic) medication use, the patients' state of health, Mini Rhin

272 %) each associated with Chiari malformation, medication use, tumor of the central nervous system, and

273 reased risk of antidepressant and anxiolytic medication use, while patients with mild AD only had inc

274 defined by worsening symptoms and increased medication use.

275 ild AD only had increased risk of anxiolytic medication use.

276 ophen (APAP) is the active component of many medications used to treat pain and fever worldwide.

277 eported pain, function, or harms of systemic medications versus placebo or another intervention.

278 with other antipsychotic or nonantipsychotic medications vs placebos or antipsychotic monotherapy amo

279 tivity scores over the first 3 months of MPH medication was correlated with the initial 90-minute MPH

280 mg [target dose], or 6 mg per day); previous medication was discontinued over 2 weeks.

281 Assigned medication was identical in appearance and packaging.

282 Rescue medication was introduced for 10 (21%), 7 (15%), and 2 (

283 o 33.7%), respectively, and antihypertensive medication was recommended for 36.2% (95% CI: 34.2% to 3

284 The need for rescue medication was reduced from 5.55 uses per month in the p

285 ic acid esters by 19 (4.9%), and more than 1 medication was used by 73 (18.7%).

286 isutility associated with receiving diabetes medications was decreased by at least 60%.

287 parate analysis, the use of antihypertensive medications was independently associated with worse allo

288 c medications, compared with nonuse of these medications, was significantly associated with higher ra

289 Out-of-pocket costs for AET medication were associated with lower adjusted odds of a

290 subsequent testing, invasive procedures, and medications were higher after coronary CTA ($995 vs. $71

291 e while receiving treatment with alternative medications were included in this trial.

292 ine and long-acting injectable antipsychotic medications were the pharmacologic treatments with the h

293 emission with CBT and treatment failure with medication, whereas negative summed functional connectiv

294 in AD have tested hypotheses regarding which medication will work best for which patients (ie, precis

295 m expanding indications for cardioprotective medications will not be realized.

296 This includes medications with documented harmful effects, including n

297 cians should always assess the use of herbal medications with patients and discuss the possible benef

298 reflect the interactions of the dopaminergic medications with the individual's susceptibility, and th

299 isease and can be suppressed by dopaminergic medication, with the degree of suppression being correla

300 Urgency incontinence medications, with timely reassessment of symptoms, can b